Glaukos COO shares product updates, 2021 pipeline

Video
Conferences|GLAUCOMA 360

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.


See more Glaucoma 360 coverage

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Related Content
ChatGPT may have a future use in glaucoma

ChatGPT may have a future use in glaucoma

Article
Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures

(EyePod) From idea to impact: Navigating ophthalmic innovation

Podcast
Nicox announces recruitment of last patient in US in Denali Phase 3 trial of NCX 470

Nicox announces recruitment of last patient in US in Denali Phase 3 trial of NCX 470

Article
EyePod: Integrating cutting-edge pipeline devices for enhanced cataract surgery

EyePod: Integrating cutting-edge pipeline devices for enhanced cataract surgery

Podcast
Study examines nanodrug for optic nerve recovery

Study examines nanodrug for optic nerve recovery

Article
Welcome to the metaverse: Technology allows ophthalmologists to mingle with colleagues worldwide

Welcome to the metaverse: Technology allows ophthalmologists to mingle with colleagues worldwide

Article
© 2024 MJH Life Sciences

All rights reserved.